Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
News about Protagonist Therapeutics, Inc. (NASDAQ: PTGX) centers on its progress as a discovery-through-late-stage development biopharmaceutical company advancing peptide-based drug candidates. Company announcements frequently highlight clinical and regulatory milestones for its lead investigational therapies, icotrokinra and rusfertide, as well as updates from its broader pipeline and collaborations.
Investors following PTGX news will see regular coverage of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. Press releases describe data from Phase 3 ICONIC studies in moderate-to-severe plaque psoriasis, including ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2, as well as the Phase 2b ANTHEM-UC trial in ulcerative colitis. News items also report on regulatory submissions, such as the New Drug Application to the U.S. FDA and an application to the European Medicines Agency for plaque psoriasis.
Coverage of rusfertide focuses on its development for polycythemia vera in collaboration with Takeda. News releases describe Phase 3 VERIFY study results, long-term extension data from THRIVE, and the submission of a New Drug Application to the FDA for adults with polycythemia vera. These updates often include details on hematocrit control, phlebotomy requirements, patient-reported outcomes, and regulatory designations such as Breakthrough Therapy, Orphan Drug, and Fast Track status.
Additional PTGX news includes presentations at major medical and scientific conferences, such as the American Society of Hematology Annual Meeting, European Academy of Dermatology and Venereology Congress, American College of Gastroenterology meeting, and the J.P. Morgan Healthcare Conference. The company also issues periodic financial result and corporate update releases, which summarize recent clinical achievements, collaboration developments with Johnson & Johnson and Takeda, and progress in earlier-stage programs like PN-881, PN-477, and the oral hepcidin initiative.
For readers tracking PTGX, this news stream provides insight into Protagonist’s clinical data, regulatory interactions, partnership activities, and pipeline evolution as described in its own public communications.
Protagonist Therapeutics (Nasdaq: PTGX) has received FDA's Breakthrough Therapy Designation for rusfertide, aimed at treating polycythemia vera (PV) by reducing erythrocytosis. This designation, granted on June 3, 2021, accelerates development for serious conditions and is based on promising Phase 2 trial data showing significant patient improvements. Rusfertide is positioned as the first non-cytoreductive therapy for PV. Protagonist plans to expedite clinical studies, and updated data will be presented at the European Hematology Association meeting from June 9-17, 2021.
Protagonist Therapeutics (PTGX) announced the dosing of the first human subject in a Phase 1 study for PN-232, an oral interleukin-23 receptor antagonist peptide. This trial aims to assess safety, tolerability, and pharmacokinetics. The study consists of three parts: single ascending doses, multiple ascending doses, and food effect evaluations. Protagonist is collaborating with Janssen Biotech, which will handle development past Phase 2. The company may receive milestone payments and has options for product co-detailing in the U.S.
Protagonist Therapeutics (PTGX) announced that its abstract on updated data from the Phase 2 trial of rusfertide for polycythemia vera has been selected for oral presentation at the EHA 2021 Annual Congress from June 9-17, 2021. The study showed significant results, including the elimination of therapeutic phlebotomy needs and improved iron levels in patients. The presentation will be available on-demand starting June 11, 2021, and aims to further establish the efficacy of rusfertide in managing PV.
Protagonist Therapeutics (PTGX) reported its Q1 2021 financial results and highlighted significant pipeline developments. The company completed enrollment for its Phase 2 study of rusfertide in polycythemia vera and plans to initiate a Phase 3 study in early 2022 after receiving positive feedback from regulators. License revenue increased to $6.2 million, up from $3.6 million year-over-year, and cash reserves stand at $279.7 million, expected to fund operations until mid-2024. However, R&D expenses rose to $24.2 million, contributing to a net loss of $24.0 million for the quarter.
Protagonist Therapeutics (Nasdaq: PTGX) announced on April 30, 2021, the issuance of an inducement award to Ramesh Bhatt, the newly appointed Vice President of Discovery Biology and Translational Research. The award consists of an option to purchase 45,000 shares at an exercise price of $28.94, vesting over four years. This action is aligned with Nasdaq Marketplace Rule 5635(c)(4) and was approved by the Company's compensation committee. Protagonist is advancing multiple peptide-based therapeutics, including rusfertide, currently in Phase 2 trials for various hematological conditions.
Protagonist Therapeutics (Nasdaq: PTGX) has successfully completed enrollment for its Phase 2 study of rusfertide (PTG-300) in polycythemia vera (PV), exceeding the target of 50 evaluable patients. Those not included will have the chance to participate in the upcoming Phase 3 study. Preliminary data suggests rusfertide can maintain hematocrit levels, reducing thrombotic risks in PV patients. The company plans to present interim findings at a major medical meeting soon and is optimistic about moving into Phase 3 trials in early 2022, backed by regulatory agency support.
Protagonist Therapeutics (PTGX) announced plans to initiate a global Phase 3 clinical trial for rusfertide (PTG-300), targeting polycythemia vera (PV). The FDA provided key feedback, and the EMA expressed support for its clinical development plan. The Phase 3 study will enroll 200-250 adult participants, focusing on the proportion achieving response defined by hematocrit control. Secondary endpoints will include symptoms and phlebotomy frequency. The trial aims to address unmet needs in PV treatment, paving the way for future drug applications in the U.S. and Europe.
Protagonist Therapeutics (Nasdaq: PTGX) reported its financial results for Q4 2020, highlighting significant growth in its pipeline. The company received orphan drug and Fast Track designations for rusfertide in polycythemia vera (PV), affecting approximately 100,000 patients in the U.S. Protagonist aims to finalize its clinical development plan for rusfertide by mid-2021. The company raised $255 million through various public offerings in 2020, ending the year with $307.8 million in cash and equivalents. However, it reported a net loss of $66.2 million for the full year 2020.
Protagonist Therapeutics (Nasdaq: PTGX) will host a conference call on March 10, 2021, at 4:30 PM ET to discuss its Q4 and full year 2020 financial results. The call can be accessed via phone at 1-844-515-9178 (U.S.) or 1-614-999-9313 (International), with conference ID #: 7756175. A live webcast will also be available on the company's website. Protagonist is developing several peptide-based therapeutics, including PTG-300 and PTG-200, currently in various stages of clinical trials.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will participate in the virtual H.C. Wainwright Global Life Sciences Conference from March 9 to 10, 2021. CEO Dinesh V. Patel, Ph.D., will engage in a fireside chat on March 9, starting at 7:00 a.m. EST, with a subsequent opportunity for one-on-one meetings with investors. A webcast of the event will be available for 90 days. Protagonist is advancing multiple peptide-based therapeutics, including PTG-300 and PTG-200, targeting various conditions such as polycythemia vera and Crohn's disease.